Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2024 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.29824 EPS, expectations were $0.09. Amneal Pharmaceuticals, Inc.
Source: insidermonkey.com
Joe Renda News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Joe Renda. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Joe Renda Today - Breaking & Trending Today
John Regan's final interview on his career with Frampton and Frehley
The Frehley's Comet bassist died in April 2023. Just three days before his untimely passing, he spoke to Bass Player about his remarkable career, including the highs and lows of working with Ace Frehl
Source: guitarworld.com
Amneal, BIAL ink U.S. licensing agreement for Ongentys
Ongentys (opicapone) is an adjunctive therapy for the treatment of Parkinson’s disease.
Source: drugstorenews.com
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
ONGENTYS® (opicapone) is a leading adjunctive therapy for the treatment of Parkinson’s DiseaseComplements Amneal’s existing Parkinson’s franchise and further expands specialty portfolioBRIDGEWATER, N.J. & PORTO, Portugal--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela &...
Source: pharmiweb.com
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS (opicapone)
07.12.2023 - Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS (opicapone) in the U.S. starting on ... Seite 1
Source: wallstreet-online.de